Inhibition of PCSK9 in familial hypercholesterolaemia

被引：5
|
作者：
Sijbrands, Eric J. G. [1 ,2 ]
机构：
[1] Erasmus MC, Pharmacol Vasc & Metab Dis sect, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Cardiol & Internal Med, Cardiovasc Genet Sect, NL-3000 CA Rotterdam, Netherlands
来源：
LANCET | 2012年 / 380卷 / 9836期
关键词：
APOLIPOPROTEIN-B; CONTROLLED-TRIAL; LDL CHOLESTEROL; DOUBLE-BLIND; STATIN; ATHEROSCLEROSIS; MIPOMERSEN; EZETIMIBE; EFFICACY; THERAPY;
D O I：
10.1016/S0140-6736(12)60814-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [41] PCSK9 Inhibition to Reduce Cardiovascular Events
    Dullaart, Robin P. F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (18) : 1790 - 1791
  • [42] PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
    Carugo, Stefano
    Sirtori, Cesare R.
    Corsini, Alberto
    Tokgozoglu, Lale
    Ruscica, Massimiliano
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (12) : 995 - 1004
  • [43] PCSK9 Inhibition could be Effective for Acute Myocardial Infarction
    Gencer, Baris
    Mach, Francois
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (06) : 1016 - 1026
  • [44] An oral antisense oligonucleotide for PCSK9 inhibition
    Gennemark, Peter
    Walter, Katrin
    Clemmensen, Niclas
    Rekic, Dinko
    Nilsson, Catarina A. M.
    Knochel, Jane
    Holtta, Mikko
    Wernevik, Linda
    Rosengren, Birgitta
    Kakol-Palm, Dorota
    Wang, Yanfeng
    Yu, Rosie Z.
    Geary, Richard S.
    Riney, Stan J.
    Monia, Brett P.
    Isaksson, Rikard
    Jansson-Lofmark, Rasmus
    Rocha, Cristina S. J.
    Linden, Daniel
    Hurt-Camejo, Eva
    Crooke, Rosanne
    Tillman, Lloyd
    Ryden-Bergsten, Tina
    Carlsson, Bjorn
    Andersson, Ulf
    Elebring, Marie
    Tivesten, Anna
    Davies, Nigel
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (593)
  • [45] PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
    Norata, Giuseppe Danilo
    Tibolla, Gianpaolo
    Catapano, Alberico Luigi
    VASCULAR PHARMACOLOGY, 2014, 62 (02) : 103 - 111
  • [46] Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury, Sharmistha Roy
    Rees, Alan
    CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (05) : 509 - 510
  • [47] Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
    Mcclintick, Daniel J.
    Giugliano, Robert P.
    CURRENT OPINION IN LIPIDOLOGY, 2023, 34 (06) : 243 - 251
  • [48] Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
    Koskinas, Konstantinos C.
    Wilhelm, Matthias
    Windecker, Stephan
    SWISS MEDICAL WEEKLY, 2016, 146 : w14333
  • [49] Understanding PCSK9 and anti-PCSK9 therapies
    McKenney, James M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (02) : 170 - 186
  • [50] Hyperlipidemia: What role do PCSK9 inhibitors play?
    Meyer, Dirk
    Merkel, Martin
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (20) : 1430 - 1434
12345